7,589 Shares in Solventum Corporation $SOLV Acquired by StoneRidge PMG Advisors LLC

StoneRidge PMG Advisors LLC purchased a new position in Solventum Corporation (NYSE:SOLV) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 7,589 shares of the company’s stock, valued at approximately $669,000.

Other hedge funds have also recently made changes to their positions in the company. Diamond Hill Capital Management LLC Investment Advisor purchased a new stake in Solventum in the second quarter worth approximately $150,066,000. Bank of New York Mellon Corp purchased a new stake in Solventum during the 2nd quarter valued at $61,460,000. Assenagon Asset Management S.A. raised its stake in Solventum by 16,656.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 482,930 shares of the company’s stock valued at $42,570,000 after buying an additional 480,048 shares during the last quarter. Squarepoint Ops LLC raised its stake in Solventum by 6,103.8% during the 2nd quarter. Squarepoint Ops LLC now owns 243,128 shares of the company’s stock valued at $18,757,000 after buying an additional 239,209 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Solventum by 44.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 774,683 shares of the company’s stock valued at $50,576,000 after buying an additional 236,659 shares during the period.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. Wedbush raised their price target on Solventum from $94.00 to $101.00 and gave the stock an “outperform” rating in a research note on Thursday, August 6th. UBS Group increased their price objective on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Benchmark restated a “buy” rating on shares of Solventum in a research note on Thursday, October 8th. Stifel Nicolaus upped their price objective on Solventum from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Finally, Canadian Imperial Bank of Commerce set a $35.00 target price on Solventum in a report on Wednesday, October 28th. Ten analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $90.27.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Solventum earned $1.45 per share on $1.95 billion in revenue, beating consensus estimates of $1.34–$1.35 per share and $1.93 billion in sales. The company raised its 2026 adjusted EPS guidance to $7.20–$7.30 and expects organic sales growth toward the high end of its 2.5%–3.0% range. Solventum Q3 results
• Positive Sentiment: Analysts lifted price targets: Piper Sandler raised its target to $110 and reaffirmed an overweight rating; Wells Fargo increased its target to $95 while retaining an equal-weight rating. Jefferies raised its target to $98. Piper Sandler rating
• Neutral Sentiment: The company said the 7% year-over-year sales decline (organic sales down 2.8%) reflected, in part, a temporary ERP transition effect: customers had placed advance orders in the prior quarter ahead of the system cutover. Solventum also reported that its separation process was more than 90% complete. Q3 earnings and ERP impact
• Negative Sentiment: Despite the quarterly beat, revenue fell 7% year over year and EPS was down from $1.50 a year ago, highlighting ongoing comparisons and execution risks. Quarterly earnings details

Solventum Trading Down 0.0%

Shares of NYSE:SOLV opened at $90.34 on Monday. The stock has a 50 day moving average of $87.73 and a 200 day moving average of $78.70. The company has a market cap of $15.38 billion, a PE ratio of 101.51, a price-to-earnings-growth ratio of 1.31 and a beta of 0.69. The company has a current ratio of 1.03, a quick ratio of 0.72 and a debt-to-equity ratio of 0.99. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $94.16.

Solventum (NYSE:SOLV) last released its earnings results on Thursday, November 5th. The company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.11. Solventum had a net margin of 1.91% and a return on equity of 25.03%. The company had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.93 billion. During the same period in the prior year, the firm posted $1.50 EPS. The firm’s quarterly revenue was down 7.0% compared to the same quarter last year. As a group, equities research analysts expect that Solventum Corporation will post 7.25 EPS for the current year.

Solventum Company Profile

Solventum is a global healthcare company that develops products and services for hospitals, dental professionals, health systems and other care providers. It was formed from 3M’s healthcare business and became an independent public company in April 2024.

The company’s offerings include medical and surgical supplies, wound-care products, sterilization and infection-prevention solutions, dental materials and technologies, and software for health information management. Its products and services support clinical care, dental care and healthcare administration.

Solventum serves customers in the United States and international markets.